Biltricide (racemate praziquantel) oral tablets + Racemate Praziquantel ODT + Levo Praziquantel ODT
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Schistosomiasis
Conditions
Schistosomiasis
Trial Timeline
Jun 12, 2016 → Nov 17, 2018
NCT ID
NCT02806232About Biltricide (racemate praziquantel) oral tablets + Racemate Praziquantel ODT + Levo Praziquantel ODT
Biltricide (racemate praziquantel) oral tablets + Racemate Praziquantel ODT + Levo Praziquantel ODT is a phase 2 stage product being developed by Merck for Schistosomiasis. The current trial status is completed. This product is registered under clinical trial identifier NCT02806232. Target conditions include Schistosomiasis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02806232 | Phase 2 | Completed |
Competing Products
3 competing products in Schistosomiasis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Praziquantel 600Mg Oral Tablet x 5 + Praziquantel 600Mg Oral Tablet x 1 | Merck | Phase 2/3 | 65 |
| L-PZQ ODT 50 mg/kg + Biltricide® + L-PZQ ODT 60 mg/kg | Merck | Phase 3 | 77 |
| praziquantel | Hikma Pharmaceuticals | Phase 3 | 72 |